No Detail Found!

The Grey Clouds Looming over Pakistan’s Drug Transparency Sector

Author(s)
Mir Ibrahim Sajid Medical College, The Aga Khan University, Stadium Road, Karachi, Pakistan
Saiqa Khan Medical College, The Aga Khan University, Stadium Road, Karachi, Pakistan
Samira Shabbir Balouch KEMU/ Mayo Hospital, Lahore, Pakistan
Sajid Abaidullah KEMU/ Mayo Hospital, Lahore, Pakistan
Abstract
Pakistan has experienced major turbulence in terms of drug pricing over the course of the past two years, with prices jumping as high as 260% of their original. A country with a large majority of population living in low socioeconomic settings, with an out-of-pocket health-care finance system, non-availability of statesponsored healthcare insurance, and this price hike meant that treatment was now a privilege, rather than an essential commodity. However, the government faces serious backlashes from pharmaceutical industrialists when it retorts to appeasing the general public. With a moderation and regulation in drug pricing comes an acute shortage of medicinal availability across the country. Could this be blackmail? Or a genuine need for a price hike to optimize profits from the sale of medicines made from imported chemicals?
Publication Details
Page(s) 458-459
DOI DOI not available
Published Journal: Annals of King Edward Medical University, Volume: 27, Issue: SI, Year: 2021

Request the full text from PASTIC

Keywords
Pakistan, pharmaceuticals, Drug Sector, Transparency, Accountability.
0

Citations

0

Downloads

40

Views